Ocugen, Inc., a clinical-stage biopharmaceutical company operating within the Health Care sector, has recently filed a Form 144 notice with the Securities and Exchange Commission (SEC). This filing, dated October 9, 2026, announces the proposed sale of over four hundred thousand shares of Ocugen’s common stock by officer Shankar Musunuri. These shares were acquired as equity compensation between 2014 and 2025, and the transaction is expected to be completed shortly after the filing date.
Ocugen, Inc. is known for its innovative products designed to enhance the body’s ability to regenerate healthy cartilage, improve joint function, and prevent degenerative diseases. The company serves patients and orthopedists nationwide in the United States, positioning itself as a key player in the biotechnology industry. Founded with an Initial Public Offering (IPO) on December 3, 2014, Ocugen is listed on the Nasdaq stock exchange and has a market capitalization of approximately $324 million as of October 8, 2026.
The recent Form 144 filing follows prior sales of similar shares within the past three months. Notably, Shankar Musunuri completed a sale in September 2026, as did KVM Holdings LLC, a related party. These transactions are part of a broader trend of equity compensation sales by company insiders, reflecting ongoing adjustments in their investment portfolios.
As of October 8, 2026, Ocugen’s stock closed at $0.956, marking its 52-week low. The company’s 52-week high was recorded at $2.725 on March 16, 2026. The price-to-earnings ratio stands at -3.87, indicating the company’s current financial performance and market valuation challenges.
Ocugen’s headquarters are located in Malvern, Pennsylvania, and the company continues to focus on its mission to deliver cutting-edge biotechnological solutions. For more detailed information about their products and services, stakeholders and interested parties are encouraged to visit Ocugen’s official website at www.ocugen.com .
This recent filing and the associated share sales underscore the dynamic nature of Ocugen’s financial activities and its ongoing efforts to navigate the competitive landscape of the biotechnology sector. As the company progresses, it remains committed to advancing its clinical-stage projects and enhancing its offerings to meet the evolving needs of the healthcare market.
